If you or a loved one has been diagnosed with pancreatic cancer, we can help you understand the disease and your options. PanCAN Patient Services Case Managers are available to support you and connect ...

PanCAN welcomes Jon Mahrt, Chief Executive Officer of Optum Rx and Chief Growth Officer of Optum to the Board of Directors. In this Q&A, Jon shares his personal connection to the cause, his passion ...

We're the national organization providing support, resources, volunteer opportunities and hope for people fighting pancreatic cancer.

Editor’s Note: PanCAN volunteers devote their time, energy and passion year-round to improving the lives of everyone impacted by pancreatic cancer. To celebrate Volunteer Appreciation Week 2025 (April ...

Cancer advocates, researchers, clinicians and patients are speaking out in a new STAT News article published this week about the devastating impact the cuts to federal research funding will have on ...

Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...

Makes: 1 16 oz smoothie By: Tuesday Hoelscher, RDN Ingredients: 1/2 c Boost High Protein 1/2 c full fat Greek yogurt 2 tbsp chia seeds 1/2 c spinach 1/2 c mango 1 c blueberries 1/2 c orange juice ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit outlines the latest advances in pancreatic cancer and offers key insights from ASCO GI 2025.

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and New Treatments for Patients LOS ANGELES, Calif. – (January 16, 2025) – After ...

The U.S. Food and Drug Administration has granted accelerated approval for a new drug targeting a tumor alteration called NRG1 gene fusion found in roughly 3% of patients with pancreatic ...

Anna Berkenblit, MD, MMSc, is looking forward to bringing her dual experience as a clinician and biotech executive to her new role as PanCAN’s Chief Scientific and Medical Officer.

For the first time in more than 10 years, the FDA has approved a new first-line treatment, called NALIRIFOX, for patients with metastatic pancreatic cancer.